Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06009458
Registration number
NCT06009458
Ethics application status
Date submitted
6/04/2023
Date registered
24/08/2023
Date last updated
24/08/2023
Titles & IDs
Public title
Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Query!
Scientific title
Clinical Evaluation of Safety and Effectiveness for Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Query!
Secondary ID [1]
0
0
AVDR 2022-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Acuity200OK
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myopia
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Other: Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear - For the orthokeratology treatment the subjects will be instructed to wear the study lenses each night during the hours of sleep (for a minimum of 6 hours) and remove the lenses during the waking hours. The subject will be examined at 1 day, 1 week, 1 month, 3 months, 6 months, 9 months and 12 months after dispensing to evaluate the ocular physiology and the treatment effect. The target refractive error (sphere) will be plano for all subjects. All subjects enrolled at two of the investigational sites (targeted total of 40 subjects) will be evaluated for the stability of UCVA and manifest refraction throughout a single day on or following the 3 month, 6 month, or 9 month follow up visits. A post-treatment follow-up visit will be scheduled 1 month following discontinuation of the study lens. When it has been determined that no additional follow up visits are required, the subject will be discharged from the study.
Treatment: Devices: Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Lines of improvement of monocular UCVA at the 12-month visit (overall and stratified by baseline sphere)
Query!
Assessment method [1]
0
0
The number of lines of change in acuity (for an eye) is defined as the difference in the logMAR acuities, scored to the letter, multiplied by 10. Each line difference represents 0.1 logMAR acuity. The improvement in acuity is represented by a numerical reduction in the logMAR value.
The primary effectiveness endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults) .
Query!
Timepoint [1]
0
0
1 year
Query!
Primary outcome [2]
0
0
Attempted vs. Achieved Reduction in manifest refractive error
Query!
Assessment method [2]
0
0
proportion of eyes with manifest sphere within ±0.50 D, ±1.00 D, and ±2.00 D of the target (plano) at the 12-month post-dispensing visit (overall and stratified by baseline sphere).
The primary effectiveness endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults) .
Query!
Timepoint [2]
0
0
1 Year
Query!
Primary outcome [3]
0
0
Proportion of eyes achieved UCVA of =0.30 logMAR , =0.20 logMAR ,=0.10 logMAR, and =0.00 logMAR
Query!
Assessment method [3]
0
0
Proportion of eyes at the 1-month visit (and later visit intervals) that have achieved UCVA of =0.30 logMAR, =0.20 logMAR, =0.10 logMAR, and =0.00 logMAR for the whole cohort and stratified by pre-treatment refractive bin.
The primary effectiveness endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and22 years and older (adults) .
Query!
Timepoint [3]
0
0
1 Year
Query!
Primary outcome [4]
0
0
Treatment stability
Query!
Assessment method [4]
0
0
Treatment stability as measured by the percentage of eyes that change by less than ±0.50 diopters manifest refraction spherical equivalent (MRSE) between two consecutive visits (baseline and 1-month, 1 and 3-month, 3 and 6-month, 6 and 9-month, and 9 and 12-month)
The primary effectiveness endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults) .
Query!
Timepoint [4]
0
0
1 Year
Query!
Primary outcome [5]
0
0
Number and rates (by type of event and relation to device) of serious and significant adverse events occurred at any visit
Query!
Assessment method [5]
0
0
Number and rates (by type of event and relation to device) of serious and significant adverse events occurred at any visit.
The primary safety endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults).
Query!
Timepoint [5]
0
0
1 Year
Query!
Primary outcome [6]
0
0
Number and rates (by type of event) of all types of adverse events that were not classified as serious or significant adverse events.
Query!
Assessment method [6]
0
0
Number and rates (by type of event) of all types of adverse events that were not classified as serious or significant adverse events.
The primary safety endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults).
Query!
Timepoint [6]
0
0
1 Year
Query!
Primary outcome [7]
0
0
All slit lamp results will be tabulated and findings above grade 2 will be evaluated and explained in relation to the treatment
Query!
Assessment method [7]
0
0
All slit lamp results will be tabulated and findings above grade 2 will be evaluated and explained in relation to the treatment.
The primary safety endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults).
Query!
Timepoint [7]
0
0
1 Year
Query!
Primary outcome [8]
0
0
Number and rate of cases of loss from baseline to any post-dispensing visit of: monocular best spectacle corrected visual acuity (BSCVA) of 2 or more lines (= 0.2 logMar), and 1 or more lines (= 0.1 logMar).
Query!
Assessment method [8]
0
0
Number and rate of cases of loss from baseline to any post-dispensing visit of: monocular best spectacle corrected visual acuity (BSCVA) of 2 or more lines (= 0.2 logMar), and 1 or more lines (= 0.1 logMar).
The primary safety endpoints described above will also be stratified by subjects' baseline age (including 7 to 11 years (children), 12 to 21 years (adolescents), and 22 years and older (adults).
Query!
Timepoint [8]
0
0
1 Year
Query!
Secondary outcome [1]
0
0
A set of descriptive statistics of improvement of monocular UCVA at all visits (1 month or later), as well as stratified by baseline sphere and by spherical equivalent.
Query!
Assessment method [1]
0
0
A set of descriptive statistics of improvement of monocular UCVA at all visits (1 month or later), as well as stratified by baseline sphere and by spherical equivalent.
Query!
Timepoint [1]
0
0
1 Year
Query!
Secondary outcome [2]
0
0
Change in best corrected spectacle visual acuity (BCSVA) from at all visits stratified by baseline pretreatment diopteric group.
Query!
Assessment method [2]
0
0
Change in best corrected spectacle visual acuity (BCSVA) from at all visits stratified by baseline pretreatment diopteric group.
Query!
Timepoint [2]
0
0
1 Year
Query!
Secondary outcome [3]
0
0
Pre-treatment manifest sphere in comparison to post-treatment manifest sphere stratified by dioptric power for all completed subjects at the 1 month visit and later visit intervals (3, 6, 9, and 12 month visits)
Query!
Assessment method [3]
0
0
Pre-treatment manifest sphere in comparison to post-treatment manifest sphere stratified by dioptric power for all completed subjects at the 1 month visit and later visit intervals (3, 6, 9, and 12 month visits)
Query!
Timepoint [3]
0
0
1 Year
Query!
Secondary outcome [4]
0
0
A level of attempted versus achieved reduction in manifest refractive error- proportion of eyes with manifest sphere within ±0.50 D, ±1.00 D, and ±2.00 D of the target (plano) at all other visits (1 month or later)
Query!
Assessment method [4]
0
0
A level of attempted versus achieved reduction in manifest refractive error- proportion of eyes with manifest sphere within ±0.50 D, ±1.00 D, and ±2.00 D of the target (plano) at all other visits (1 month or later) (overall and stratified by baseline sphere).
Query!
Timepoint [4]
0
0
1 Year
Query!
Secondary outcome [5]
0
0
Corneal topography changes (in simulated keratometry flat and steep meridia) from baseline to 12-month post-dispensing visit (overall and stratified by baseline sphere).
Query!
Assessment method [5]
0
0
Corneal topography changes (in simulated keratometry flat and steep meridia) from baseline to 12-month post-dispensing visit (overall and stratified by baseline sphere).
Query!
Timepoint [5]
0
0
1 Year
Query!
Secondary outcome [6]
0
0
An analysis of corneal topography for changes in eccentricity from baseline to 12-month visit
Query!
Assessment method [6]
0
0
An analysis of corneal topography for changes in eccentricity from baseline to 12-month visit
Query!
Timepoint [6]
0
0
1 Year
Query!
Secondary outcome [7]
0
0
An analysis of change in absolute corneal astigmatism from baseline to 12-month visit
Query!
Assessment method [7]
0
0
An analysis of change in absolute corneal astigmatism from baseline to 12-month visit
Query!
Timepoint [7]
0
0
1 Year
Query!
Secondary outcome [8]
0
0
Number of discontinued subjects and the reasons of discontinuation.
Query!
Assessment method [8]
0
0
Number of discontinued subjects and the reasons of discontinuation.
Query!
Timepoint [8]
0
0
1 Year
Query!
Secondary outcome [9]
0
0
An analysis of the relationship between changes in simulated keratometry and corresponding reductions in manifest sphere at all scheduled visits (1 month and later).
Query!
Assessment method [9]
0
0
An analysis of the relationship between changes in simulated keratometry and corresponding reductions in manifest sphere at all scheduled visits (1 month and later).
Query!
Timepoint [9]
0
0
1 Year
Query!
Secondary outcome [10]
0
0
Number and rates of average wear time per day at all scheduled visits (1 day and later)
Query!
Assessment method [10]
0
0
Number and rates of average wear time per day at all scheduled visits (1 day and later).
Query!
Timepoint [10]
0
0
1 Year
Query!
Secondary outcome [11]
0
0
An analysis of the effects of wearing time on uncorrected visual acuity (UCVA) at all visits (1 month and later)
Query!
Assessment method [11]
0
0
An analysis of the effects of wearing time on uncorrected visual acuity (UCVA) at all visits (1 month and later).
Query!
Timepoint [11]
0
0
1 Year
Query!
Secondary outcome [12]
0
0
Stability of monocular UCVA change by post-lens removal hours for the sub-group of up to 40 participants at a single day visit (at 3-month or any later visits) - stratified by baseline MRSE.
Query!
Assessment method [12]
0
0
Stability of monocular UCVA change by post-lens removal hours for the sub-group of up to 40 participants at a single day visit (at 3-month or any later visits) - stratified by baseline MRSE.
Query!
Timepoint [12]
0
0
1 Year
Query!
Secondary outcome [13]
0
0
Stability of manifest refractive spherical equivalent (MRSE) change by post-lens removal hours for the sub-group of up to 40 participants at a single day visit (at 3-month or any later visits) - stratified by baseline MRSE.
Query!
Assessment method [13]
0
0
Stability of manifest refractive spherical equivalent (MRSE) change by post-lens removal hours for the sub-group of up to 40 participants at a single day visit (at 3-month or any later visits) - stratified by baseline MRSE.
Query!
Timepoint [13]
0
0
1 Year
Query!
Secondary outcome [14]
0
0
Increase in corneal/refractive astigmatism of 2D or more and 1D or more post-treatment as compared to baseline
Query!
Assessment method [14]
0
0
Increase in corneal/refractive astigmatism of 2D or more and 1D or more post-treatment as compared to baseline.
Query!
Timepoint [14]
0
0
1 Year
Query!
Secondary outcome [15]
0
0
Signs/symptoms and complications from subjective questionnaires and reported during the study
Query!
Assessment method [15]
0
0
Signs/symptoms and complications from subjective questionnaires and reported during the study.
Query!
Timepoint [15]
0
0
1 Year
Query!
Secondary outcome [16]
0
0
Descriptive statistics of IOP (Interocular Pressure) and for percent change from baseline of IOP value will be provided at 6-month, 12-month, and post-treatment 1-month visit.
Query!
Assessment method [16]
0
0
Descriptive statistics of IOP (Interocular Pressure) and for percent change from baseline of IOP value will be provided at 6-month, 12-month, and post-treatment 1-month visit.
Query!
Timepoint [16]
0
0
1 Year
Query!
Secondary outcome [17]
0
0
Descriptive statistics of specular microscopy measurements for percent change from baseline of specular microscopy measurements will be provided at 12-month visit
Query!
Assessment method [17]
0
0
Descriptive statistics of specular microscopy measurements ( Endothelial Cell Morphology Analysis (Cell density (cells/mm2), Polymegathism (CV) and Pleomorphism (percentage of hexagonal cells)) and for percent change from baseline of specular microscopy measurements will be provided at 12-month visit.
Query!
Timepoint [17]
0
0
1 Year
Query!
Secondary outcome [18]
0
0
Descriptive statistics of central corneal thickness (micron) and for percent change from baseline of central corneal thickness will be provided for post-dispensing visits at 3-month, 12-month and post-treatment 1-month visits
Query!
Assessment method [18]
0
0
Descriptive statistics of central corneal thickness (micron) and for percent change from baseline of central corneal thickness will be provided for post-dispensing visits at 3-month, 12-month and post-treatment 1-month visits.
Query!
Timepoint [18]
0
0
1 Year
Query!
Eligibility
Key inclusion criteria
1. Is age 7 or older with full legal capacity to volunteer or has parental or legal guardian written approval to volunteer; and has read, understood and signed the Informed Consent Form or Assent Form (for subjects 18 years and under);
2. Is willing and able to follow participant instructions for product usage and meet the specified schedule of follow-up visits;
3. Has naturally occurring refractive myopia from -0.75 to -6.00 diopters sphere (spectacle plane), with refractive astigmatism (spectacle plane) up to 1.75 DC-as determined by adjusted manifest refraction (phoropter or trial frame) with a 12.5 mm vertex distance.
4. Has a best spectacle corrected visual acuity of 0.04 log MAR (20/20 -2) or better in each eye;
5. Is free of eye disease and binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.) that may affect vision or contact lens wear; Has normal healthy eyes with no evidence of lid infection or structural abnormality; a conjunctiva free of infection; a cornea clear and free of edema, visually or topographically significant scars, clinically significant staining, significant vascularization, infiltrates when examined by slit-lamp biomicroscopy; and no evidence of iritis or uveitis.
Query!
Minimum age
7
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Is pregnant, breast-feeding or intends to become pregnant over the course of the study.
2. Is a potential pediatric subject that does not have the appropriate level of psychological maturity to comply with appropriate procedures needed for safe wear according to the investigator.
3. Is a potential pediatric subject that is a ward of the State or any other agency, institution, or entity.
4. Has a history of any of the following medical conditions: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including, but not limited to active thyroid disorders and diabetes), lupus, and rheumatoid arthritis. NOTE: The presence of diabetes (either type 1 or 2), regardless of disease duration, severity or control, specifically excludes subjects from eligibility.
5. Has a history of intraocular or corneal surgery (including cataract extraction and refractive surgery-such as Lasik), active ophthalmic disease or abnormality (including, but not limited to, blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), clinically significant lens opacity, clinical evidence of trauma (including scarring), or with evidence of glaucoma or propensity for narrow angle glaucoma as determined by gonioscopic examination in either eye. NOTE: This includes any subject with open angle glaucoma, regardless of medication regimen or control. Additionally, any subject with an IOP greater than 21 mm Hg at baseline is specifically excluded from eligibility.
6. Has evidence of keratoconus, corneal irregularity, or abnormal video-keratography in either eye.
7. Has a pupil size greater than 6.0 mm in photopic illumination as measured with pupil detection component of computer assisted video keratography.
8. Has a corneal diameter of 10 mm or less;
9. Has flat keratometry values flatter than 38.00D (8.88 mm), or steeper than 47.00D (7.16 mm);
10. Takes medication that may cause dry eye or affect vision, corneal curvature, or healing (i.e., corticosteroids);
11. Has an allergy to any ingredient in the study lens care solutions;
12. Has significant ocular allergy, which would contraindicate solution use and/or "normal" contact lens wear;
13. Is currently using or has a history of atropine use for myopia progression control
14. Is a current wearer or previous wearer within the last 90 days of daily wear rigid gas permeable contact lenses, extended wear rigid gas permeable contact lenses, or orthokeratology contact lenses;
15. Is participating in any other type of clinical or research study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/09/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2025
Query!
Actual
Query!
Sample size
Target
375
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Innovative Eye Care - Adelaide
Query!
Recruitment hospital [2]
0
0
Richard Lindsay and Associates - Balwyn North
Query!
Recruitment hospital [3]
0
0
Custom Eyecare Newcastle - Cooks Hill
Query!
Recruitment hospital [4]
0
0
Eyeconic Optometry - Southport
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3104 - Balwyn North
Query!
Recruitment postcode(s) [3]
0
0
2300 - Cooks Hill
Query!
Recruitment postcode(s) [4]
0
0
4215 - Southport
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Texas
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Hamilton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Acuity Polymers, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this clinical investigation is to collect scientifically valid safety and effectiveness data on the Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a new Premarket Application (PMA).
Query!
Trial website
https://clinicaltrials.gov/study/NCT06009458
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Mijeong Kwon Andre, MS
Query!
Address
0
0
Andre Vision and Device Research
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
James Bonafini
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
(585) 458-8409
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06009458
Download to PDF